glp-1 depression Most Medications Correlated with a Lower Likelihood of Anxiety and Diagnoses Glucagon-like peptide-1 medicines in neurological
Description
Front Endocrinol (Lausanne)

2021;101:pzab061

le Roux CW, Astrup A, Fujioka K, et al

10.3390/medicina60030393

Lorcaserin was approved by the FDA in 2012 for use as an adjunct to a diet and exercise program for the treatment of obesity
